key: cord-0841161-3mwq9qkl
authors: Bezerra, M. F.; Machado, L. C.; Carvalho, V.; Docena, C.; Brandao-Filho, S.; Ayres, C. F. J.; Paiva, M. H. S.; Wallau, G. L.
title: A Sanger-based approach for scaling up screening of SARS-CoV-2 variants of interest and concern
date: 2021-03-25
journal: nan
DOI: 10.1101/2021.03.20.21253956
sha: 4f96860d266e1ade66315e8150cadd3d86a68734
doc_id: 841161
cord_uid: 3mwq9qkl

The global spread of new SARS-CoV-2 variants of concern underscore an urgent need of simple deployed molecular tools that can differentiate these lineages. Several tools and protocols have been shared since the beginning of the COVID-19 pandemic, but they need to be timely adapted to cope with SARS-CoV-2 evolution. Although whole-genome sequencing (WGS) of the virus genetic material have been widely used, it still presents practical difficulties such as high cost, shortage of available reagents in the global market, need of a specialized laboratorial infrastructure and well-trained staff. These limitations result in genomic surveillance blackouts across several countries. Here we propose a rapid and accessible protocol based on Sanger sequencing of a single PCR fragment that is able to identify and discriminate all SARS-CoV-2 variants of concern (VOCs) identified so far, according to each characteristic mutational profile at the Spike-RBD region (K417N/T, E484K, N501Y, A570D). Twelve COVID-19 samples from Brazilian patients were evaluated for both WGS and Sanger sequencing: three from P.2, two from P.1 and seven from B.1.1 lineage. All results from the Sanger sequencing method perfectly matched the mutational profile of VOCs and non-VOCs described by WGS. In summary, this approach allows a much broader network of laboratories to perform molecular surveillance of SARS-CoV-2 VOCs and report results within a shorter time frame, which is of utmost importance in the context of rapid public health decisions in a fast evolving worldwide pandemic.

sequencing of a single PCR fragment that is able to identify and discriminate all SARS-CoV-2 28 variants of concern (VOCs) identified so far, according to each characteristic mutational profile 29 at the Spike-RBD region (K417N/T, E484K, N501Y, A570D). Twelve COVID-19 samples from 30 Brazilian patients were evaluated for both WGS and Sanger sequencing: three from P.2, two 31 from P.1 and seven from B.1.1 lineage. All results from the Sanger sequencing method perfectly 32 matched the mutational profile of VOCs and non-VOCs described by WGS. In summary, this 33 approach allows a much broader network of laboratories to perform molecular surveillance of 34 SARS-CoV-2 VOCs and report results within a shorter time frame, which is of utmost 35 importance in the context of rapid public health decisions in a fast evolving worldwide 36 pandemic.

Keywords: SARS-CoV-2 variants of concern; Sanger sequencing; molecular surveillance. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

In order to access whether the amplicon used in this study is able to cover key SARS- (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Samples were assigned to a lineage according to the mutational profile (Table 1) .

According to the WGS, from the twelve COVID-19 samples evaluated, seven were from (Table 1) .

Within the sequencing of a single 725 base pairs PCR fragment (Figure 1 ), this approach 105 could successfully detect VOC-associated mutations and correctly classify samples according to (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. need of one specific probe or primer for each mutation to be evaluated and previous knowledge 110 of the circulating mutations (10). Furthermore, high-quality electropherograms were obtained 111 without a PCR purification step, reducing costs and time of sample processing, which is 112 particularly useful for large-scale application of the method. Another advantage of this approach 113 is that primers can be easily adjusted without major protocol modifications, in case newly 114 described mutations need to be detected. On the other hand, it is important to highlight that 115 Sanger sequencing is normally more time consuming than allelic-specific RT-PCR and hence 116 with a comparative reduced scaling capacity, but it brings some advantages such as more genetic 117 data that helps to tease apart different VOCs and the possibility of detecting new emerging RBD 118 mutations.

It is important to highlight that this approach does not substitute WGS and other PCR-120 based assays and could be used in combination to further validate the VOCs results mainly with 121 WGS to uncover other important mutation at the SAR-CoV-2 genome, but it will allows a much 

Early transmissibility assessment of 155 the N501Y mutant strains of SARS-CoV-2 in the United Kingdom

South Africa responds to the new SARS-CoV-2 variant. The Lancet

Genomics and epidemiology of a novel SARS-CoV-2 lineage in Manaus, Brazil. 161 medRxiv

A Novel SARS-CoV-2 Variant of Concern

Identified in New York

Increased Resistance of SARS-CoV-2 Variant P

 128 We would like to thank the COVID-IAM and LACEN-PE teams for providing the 129 samples to sequence the SARS-CoV-2 genomes, the Technological Platform Core and the 130 All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted March 25, 2021. ; https://doi.org/10.1101/2021.03.20.21253956 doi: medRxiv preprint